About
Naki Therapeutics develops allogeneic, off-the-shelf CAR-NK cell immunotherapies targeting the CD147 marker for the treatment of solid tumors such as hepatocellular carcinoma.
Explore Naki Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.